Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.60 |
| ▸ | BACE1 | P56817 | 4/20 | 0.60 |
| ▸ | BCHE | P06276 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.53 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473102 | 0.87 | ACHE (0.66) | ACHEBACE1BCHEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3474512 | 0.86 | ACHE (0.64) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL14124454 | 0.82 | ACHE (0.63) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL6388538 | 0.80 | ACHE (0.88) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL4690024 | 0.78 | ACHE (0.69) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL4906473 | 0.77 | BACE1 (0.61) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL1803081 | 0.75 | ACHE (1.00) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL13202572 | 0.75 | MEN1 (0.61) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL3145609 | 0.75 | MEN1 (0.54) | ACHEBACE1BCHEMEN1KMT2A | |
| Methylamine SCHEMBL27725391 | 0.74 | ACHE (0.64) | ACHEBACE1BCHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
| EP-1945613-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007053082-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | ACHE 3964/4885BACE1 2227/4885BCHE 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.